PanTher Therapeutics Awarded $14.2M from CPRIT to Advance Targeted, Localized and Sustained Cancer Treatment
PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing next-generation targeted therapies for solid tumors, received a $14.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The funding will be used to expand clinical development through Phase 2 of PanTher’s lead investigational therapy, PTM-101, a minimally invasive, implantable treatment for non-metastatic pancreatic cancer that provides direct, sustained release of a known therapeutic agent at the tumor site.
Read More about PanTher Therapeutics Awarded $14.2M from CPRIT to Advance Targeted, Localized and Sustained Cancer Treatment
PanTher Therapeutics Secures Patent for Anticancer Drug-Eluting Stent
PanTher announced that a methods-of-use patent for a deployable anticancer drug-eluting stent, exclusively licensed to PanTher, has been issued by the USPTO. The patent increases the potential applicability of PanTher’s proprietary Sagittari™ treatment platform, which focuses on direct, localized, and sustained delivery of proven and novel therapeutic agents to attack cancer at the source. PanTher also announced Dan Wildman as a strategic advisor. A seasoned executive with more than 35 years of experience in the MedTech industry, Mr. Wildman previously led the Digital Surgery Strategy initiative at Johnson & Johnson and served as worldwide president of DePuy Synthes Spine and Ethicon Biosurgery.
Read More about PanTher Therapeutics Secures Patent for Anticancer Drug-Eluting Stent
PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer
PanTher announced today the dosing of the first two patients in its Phase 1 clinical trial of PTM-101 for the treatment of pancreatic cancer. This first-in-human trial will evaluate feasibility, safety, and pharmacokinetics of PTM-101 when used as part of a standard procedure for treatment of patients with locally advanced pancreatic adenocarcinoma. “Launching the PTM-101 Phase 1 trial signals a major step toward our goal of improving therapeutic options for patients with difficult-to-treat solid tumors,” said Laura Indolfi, PhD, Chief Executive Officer of PanTher Therapeutics. “We are thrilled to partner with Dr. Charles Pilgrim and his team at The Alfred Hospital in Melbourne as we incorporate PTM-101 into the treatment for patients with locally advanced pancreatic cancer.”
Read More about PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer
PanTher Therapeutics Receives Ethics Approval to Initiate Phase 1 Clinical Trial of PTM-101 in Australia
PanTher announced today that it received approval from the Human Research Ethics Committee (HREC) to open a Phase 1 clinical trial of PTM-101 in Australia. PTM-101 is being developed for the treatment of pancreatic cancer. The company also announced today the appointment of J. Marc Pipas, MD, as Chief Medical Officer and the establishment of its clinical advisory board. Dr. Pipas, a veteran GI oncologist and clinical trialist who has assisted in the development of multiple oncology agents from Phase 1 trials through commercialization (including ONIVYDE®, which received approval from the FDA for pancreatic cancer and was subsequently sold to Ipsen Pharmaceuticals for $1 billion), will direct PanTher’s clinical development programs.
Read More about PanTher Therapeutics Receives Ethics Approval to Initiate Phase 1 Clinical Trial of PTM-101 in Australia
PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer
PanTher announces today that it has closed an oversubscribed $5.4M Series A round led by Catalyst Health Ventures (CHV), with participation by Angel Physicians Fund (APF) and other notable investors. The Series A round brings the total amount raised by the company to $7.4M. Proceeds from the funding will go toward the company’s first-in-human clinical trial. The company also announced today the additions of Darshana Zaveri, Managing Partner at CHV, Manish Bhandari, Managing Partner at APF, and Maria Palasis, President and CEO of Lyra Therapeutics, to its board of directors. “PanTher represents a truly new therapeutic modality that has the potential to change the way we deliver lifesaving drugs to tumors,” noted Zaveri.
Read More about PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer
Amgen Awards PanTher with ‘Golden Ticket’ for LabCentral
Amgen and LabCentral announced that Kernal Biologics and PanTher Therapeutics each won the Amgen Golden Ticket at LabCentral. The two Golden Ticket winners were chosen by an Amgen internal committee and live audience members at a “Quick Pitch” event hosted by Amgen at its Cambridge, Mass., facility on Dec. 11, 2018. Six finalists pitched their business plans to attendees where the audience members’ votes served as input for the Amgen internal committee’s decision.